SAGE Therapeutics (SAGE) Tops Q4 EPS by 24c
Tweet
Share
E-mail
Get Alerts SAGE Hot Sheet
Join SI Premium – FREE
SAGE Therapeutics (NASDAQ: SAGE) reported Q4 EPS of ($1.75), $0.24 better than the analyst estimate of ($1.99).
For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance
- Creatd files Form S-1 and reports Q1 2026 financial results
- Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
